Global Pneumococcal Vaccine Market to Reach $11.6 Billion at a CAGR of 5.32%

News provided by

Oct 05, 2022, 14:30 ET

DUBLIN, Oct. 5, 2022 /PRNewswire/ -- The "Pneumococcal Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global pneumococcal vaccine market size reached US$ 8.5 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 11.6 Billion by 2027, exhibiting a CAGR of 5.32% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

According to the World Health Organization (WHO), children under 2-5 years of age are at a high risk of developing pneumococcal disease. This, in confluence with the escalating number of birth rates and the growing concerns among parents about the health of their children, represents one of the major factors bolstering the market growth.

Additionally, the increasing geriatric population is contributing to the market growth. This can also be accredited to the contagiousness of the disease, which can cause severe complications in older adults.

Furthermore, the rising number of smokers and individuals living with chronic health conditions is positively influencing the market growth. Moreover, the introduction of the Pneumococcal Conjugate Vaccine (PCV) in infant routine immunization by governing agencies of numerous countries is anticipated to propel the market growth.

Key Market Segmentation

Breakup by Vaccine Type:

Pneumococcal Conjugate Vaccine
Pneumococcal Polysaccharide Vaccine

Breakup by Product Type:

Prevnar 13
Synflorix
Pneumovax 23

Breakup by Distribution Channel:

Distribution Partner Companies
Non-Governmental Organizations (NGO)
Government Authorities

Breakup by End User:

Pediatrics
Adults

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Pneumococcal Vaccine Market

6 Market Breakup by Vaccine Type

7 Market Breakup by Product Type

8 Market Breakup by Distribution Channel

9 Market Breakup by End User

10 Market Breakup by Region

11 SWOT Analysis

12 Value Chain Analysis

13 Porters Five Forces Analysis

14 Price Analysis

15 Competitive Landscape

Companies Mentioned

Astellas Pharma Inc.
GlaxoSmithKline Plc.
Merck & Co. Inc.
Panacea Biotec Ltd.
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Pvt Ltd
Walvax Biotechnology Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/wk5zvc

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets